Back to top
more

Inovio Pharmaceuticals (INO)

(Delayed Data from NSDQ)

$11.32 USD

11.32
579,107

+0.37 (3.38%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $11.33 +0.01 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for INO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Inovio Pharmaceuticals, Inc. [INO]

Reports for Purchase

Showing records 141 - 160 ( 364 total )

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 141

06/27/2019

Company Report

Pages: 6

VGX-3100 REVEAL 1 Phase 3 Study Completes Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 142

06/11/2019

Company Report

Pages: 6

Government Grant Awarded to Advance Commercial Skin Delivery Device; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 143

05/29/2019

Company Report

Pages: 6

AstraZeneca Preclinical Candidate Program Discontinuations Don?t Affect MEDI0457; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 144

05/28/2019

Company Report

Pages: 9

Price: 24.95

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 145

05/22/2019

Company Report

Pages: 6

Subjects Dosed in First-in-Human Study of Lassa Fever Vaccine; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 146

05/22/2019

Company Report

Pages: 9

Price: 24.95

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 147

05/17/2019

Company Report

Pages: 6

Collaboration in Development of Companion Diagnostics for VGX-3100 Inked; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 148

05/16/2019

Company Report

Pages: 6

Development of Vaccine for African Swine Fever Initiated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 149

05/10/2019

Company Report

Pages: 6

1Q19 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 150

05/07/2019

Company Report

Pages: 5

VGX-3100 Quality and Non-Clinical Data Certified in Europe; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 151

04/22/2019

Company Report

Pages: 6

Positive Preclinical Results of dBiTEs Published; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 152

04/18/2019

Company Report

Pages: 7

VGX-3100 Awarded ''''Best Therapeutic Vaccine''''; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 153

04/16/2019

Company Report

Pages: 7

Price: 24.95

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 154

04/09/2019

Company Report

Pages: 5

Third Phase 2 Trial of MEDI0457 Initiated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 155

04/04/2019

Company Report

Pages: 6

Positive Human Data in HPV 6-Related Respiratory Tract Tumors; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 156

04/03/2019

Company Report

Pages: 6

Positive Preclinical Data of DNA-Encoded Bispecific T Cell Engagers Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 157

04/02/2019

Company Report

Pages: 6

Combination Immunotherapy in Glioblastoma Completes Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 158

03/22/2019

Company Report

Pages: 6

Positive Ebola Vaccine Phase 1 Data Published; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 159

03/15/2019

Company Report

Pages: 7

Price: 24.95

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 160

03/13/2019

Company Report

Pages: 6

2018 Financial Results; Multiple Data Readouts in 2019; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party
// eof